Cocrystal appoints Carol L. Brosgart to its board of directors

Cocrystal Pharma, Inc. (Nasdaq: COCP) appointed Carol L. Brosgart as a director on August 12, 2026, effective immediately. The company reported the appointment in a Form 8-K filed August 18, 2026, under Item 5.02, which covers the election and appointment of directors and officers. The filing is signed by James Martin, Chief Financial Officer.

The appointment

The 8-K states that there are no arrangements or understandings between Ms. Brosgart and any other person under which she was selected as a director. It reports no family relationships between her and the company's directors or executive officers, and no related party transactions that would require disclosure under Item 404(a) of Regulation S-K. The filing does not describe her professional background, any committee assignment or her director compensation.

The 8-K reports no other item beyond the appointment. Its exhibit list contains only the cover page interactive data file. The filing does not include financial results, financing terms or any clinical update.

About Cocrystal

The company's annual report filed March 31, 2026 describes Cocrystal as a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics for serious and chronic viral diseases. It employs structure-based technologies and says it has identified antiviral compounds for unmet medical needs caused by RNA viruses, including influenza, norovirus, coronaviruses, respiratory virus infections and hepatitis C virus infections. The company operates as one business entity.

The report says the company uses computational chemistry, medicinal chemistry, X-ray crystallography and cocrystal structure determination to design drugs that bind conserved regions of viral enzymes. Its stated goal is best-in-class, broad-spectrum antiviral drugs with a high barrier to resistance. The report says drug resistance is a major obstacle, because a mutation in a region of the viral genome targeted by a therapy may make that therapy ineffective against the mutated virus. The report says it has applied its technology to develop antiviral inhibitors of four viruses: influenza, coronavirus, norovirus and hepatitis C virus. Its discovery process focuses on highly conserved regions of viral drug target enzymes and inhibitor-enzyme interactions at the atomic level. The report says this differs from traditional empirical approaches that need lengthy compound screening. Those are the company's claims about its method, and the filings here report no efficacy results from it.

Dr. Roger Kornberg, the company's Chief Scientist and Chairman of both its Scientific Advisory Board and its Board of Directors, guided the development of the structure-based drug design approach. He received the Nobel Prize in Chemistry in 2006.

The report explains why resistance matters. Viruses reproduce rapidly, and mutations in a targeted region can make a therapy ineffective. The report cites the 2009 swine influenza pandemic, in which the predominant strain was resistant to the best available therapies, and the Omicron variant of COVID-19 that arose in late 2021, which displayed increased resistance to available vaccines and treatments.

Financial position

XBRL data from the 10-K show research and development expense of $5.1 million for 2025 and $12.5 million for 2024. The net loss was $8.8 million for 2025 and $17.5 million for 2024. Cash used in operations was $8.2 million for 2025 and $16.5 million for 2024. Cash and cash equivalents were $7.0 million at December 31, 2025, compared with $9.9 million at the end of 2024, against $8.2 million of cash used in operations in 2025. Research and development spending fell from $12.5 million to $5.1 million, and the filings here give no financing plan or clinical results.

Report an error

Companies in this story

COCPCocrystal Pharma, Inc.NASDAQ · United StatesOpen the starter desk